BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 990177)

  • 1. An epidemiological study of the haemostatic and other effects of oral contraceptives.
    Meade TW; Brozović M; Chakrabarth R; Howarth DJ; North WR; Stirling Y
    Br J Haematol; 1976 Nov; 34(3):353-64. PubMed ID: 990177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA; Bonnar J
    Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
    Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemostatic changes and the oral contraceptive pill.
    Norris LA; Bonnar J
    Baillieres Clin Obstet Gynaecol; 1997 Sep; 11(3):545-64. PubMed ID: 9488791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
    Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
    Notelovitz M; Kitchens CS; Khan FY
    Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 micrograms ethinyl estradiol and 2.00 mg dienogest on the hemostatic system.
    Spona J; Feichtinger W; Kindermann C; Schneider B; Mellinger U; Walter F; Moore C; Gräser T
    Contraception; 1997 Aug; 56(2):67-75. PubMed ID: 9315414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coagulation studies in women using combination type of oral contraceptives.
    Sharma S; Sharma M; Soni IJ; Gupta A; Jain R
    J Obstet Gynaecol India; 1983 Aug; 33(4):519-24. PubMed ID: 12339832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
    Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
    Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive.
    Cachrimanidou AC; Hellberg D; Nilsson S; von Schoulz B; Crona N; Siegbahn A
    Contraception; 1994 Aug; 50(2):153-65. PubMed ID: 7956214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of low-dose oral contraceptives on coagulation and fibrinolysis in two high-risk populations: young female smokers and older premenopausal women.
    Notelovitz M; Levenson I; McKenzie L; Lane D; Kitchens CS
    Am J Obstet Gynecol; 1985 Aug; 152(8):995-1000. PubMed ID: 4025463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on plasma coagulation and fibrinolysis during oral contraception of various types with special reference to cold activation of factor VII.
    Gjonnaess H; Fagerhol MK
    Scand J Haematol; 1974; 12(3):232-40. PubMed ID: 4831827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of triphasic levonorgestrel in oral contraception: a review of metabolic and hemostatic effects.
    Lachnit-Fixson U
    Gynecol Endocrinol; 1996 Jun; 10(3):207-18. PubMed ID: 8862497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen.
    Meade TW; Haines AP; North WR; Chakrabarti R; Howarth DJ; Stirling Y
    Lancet; 1977 Nov; 2(8045):948-51. PubMed ID: 72289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coagulation and anticoagulation effects of contraceptive steroids.
    Samsioe G
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1523-7. PubMed ID: 8178901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives.
    Harris GM; Stendt CL; Vollenhoven BJ; Gan TE; Tipping PG
    Am J Hematol; 1999 Mar; 60(3):175-80. PubMed ID: 10072106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral contraception and coagulation.
    Notelovitz M
    Clin Obstet Gynecol; 1985 Mar; 28(1):73-83. PubMed ID: 3987135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood pressure in women using oral contraceptives: results from the Health Survey for England 1994.
    Dong W; Colhoun HM; Poulter NR
    J Hypertens; 1997 Oct; 15(10):1063-8. PubMed ID: 9350579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemostatic effects of smoking and oral contraceptive use.
    Fruzzetti F
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S369-74. PubMed ID: 10368523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of oral contraceptives on blood coagulation. A review.
    Beller FK; Ebert C
    Obstet Gynecol Surv; 1985 Jul; 40(7):425-36. PubMed ID: 3895067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.